Tysabri and PML: Understanding the Risk Factors in Virginia

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Exposure Concerns

If you or a loved one is taking Tysabri and concerned about progressive multifocal leukoencephalopathy (PML), understanding the specific risk factors is crucial. Building on decades of research into immunosuppressive therapies, this page clarifies the difference between PML symptoms and diagnosis, and outlines the key risk factors that patients and providers in Virginia should monitor.

Tysabri and Progressive Multifocal Leukoencephalopathy: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations for filing a claim—is essential. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by reactivation of the JC virus in immunocompromised individuals, and Tysabri's mechanism of action—blocking lymphocyte migration into the central nervous system—is believed to impair immune surveillance, allowing the virus to proliferate unchecked. Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with cumulative exposure. The label advises that "these factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML typically includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is confirmed by MRI findings and detection of JC virus DNA in cerebrospinal fluid. The label emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite such monitoring, PML can still occur, and outcomes are often poor, with many patients experiencing permanent disability or death.

Legal Considerations and Statute of Limitations in Virginia

The adequacy of warnings regarding Tysabri and PML is a central issue in legal claims. The boxed warning and the TOUCH Prescribing Program—a restricted distribution system requiring patient enrollment, medication guide review, and certified pharmacies and infusion centers—are designed to mitigate risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, plaintiffs may argue that these warnings were insufficient or that the risks were not adequately communicated to patients and prescribers, particularly in the context of evolving knowledge about risk factors. For affected patients in Virginia, the statute of limitations for filing a product liability or personal injury lawsuit related to Tysabri-induced PML is generally two years from the date the injury was discovered or reasonably should have been discovered. This discovery rule is critical because PML symptoms may develop gradually, and the link to Tysabri may not be immediately apparent. The timeline between exposure and documented harm can vary; PML can occur after months or years of treatment, and the label notes that herpes infections have been reported "from a few months to several years" after starting Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For PML, the risk increases with longer treatment duration, especially beyond two years. Settlement considerations for affected patients include the severity of injury, medical expenses, lost income, and pain and suffering. Given that PML "usually leads to death or severe disability," claims often involve substantial damages. Virginia law also imposes a statute of repose for product liability claims, which may limit claims filed more than a certain number of years after the product's sale or delivery. Consulting with an attorney experienced in pharmaceutical litigation is essential to ensure timely filing. In summary, Tysabri-associated PML is a serious, often devastating condition with well-defined risk factors. Patients in Virginia who have developed PML should be aware of the two-year statute of limitations from discovery of the injury and the importance of documenting the timeline of exposure and harm. The medical evidence underscores the need for careful risk-benefit assessment and vigilant monitoring, but when harm occurs, legal recourse may be available.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Virginia?

In Virginia, the statute of limitations for filing a product liability or personal injury lawsuit related to Tysabri-induced PML is generally two years from the date the injury was discovered or reasonably should have been discovered. This discovery rule is important because PML symptoms may develop gradually and the link to Tysabri may not be immediately apparent. Consulting with an attorney promptly is crucial to ensure timely filing.

What are the primary risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with cumulative exposure. These factors should be considered when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.